Michael F MacLean insider trades: Avidity Biosciences (RNA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | RNA | ↓ Sell10b5-1 | 4,542 | $72.45 | $329K | Direct | Jan 23, 2026 (2d) |
| Aug 6, 2025 | RNA | ↓ Sell | 30,914 | $42.73 | $1.3M | Direct | Aug 15, 2025 (9d) |
| Mar 20, 2025 | RNA | ↓ Sell10b5-1 | 7,935 | $31.06 | $246K | Direct | Mar 21, 2025 (1d) |
| Jan 21, 2025 | RNA | ↓ Sell10b5-1 | 3,287 | $28.59 | $94K | Direct | Jan 23, 2025 (2d) |
| Dec 18, 2024 | RNA | ↓ Sell10b5-1 | 11,151 | $32.66 | $364K | Direct | Dec 19, 2024 (1d) |
| Nov 6, 2024 | RNA | ↓ Sell | 106,319 | $45.56 | $4.8M | Direct | Nov 8, 2024 (2d) |
| Sep 23, 2024 | RNA | ↓ Sell10b5-1 | 11,510 | $44.00 | $506K | Direct | Sep 23, 2024 (0d) |
| Jun 18, 2024 | RNA | ↓ Sell10b5-1 | 11,228 | $39.13 | $439K | Direct | Jun 20, 2024 (2d) |
| Jun 12, 2024 | RNA | ↓ Sell | 104,245 | $35.72 | $3.7M | Direct | Jun 14, 2024 (2d) |
| May 14, 2024 | RNA | ↓ Sell | 75,000 | $28.28 | $2.1M | Direct | May 16, 2024 (2d) |
| Mar 13, 2024 | RNA | ↓ Sell | 40,000 | $24.52 | $981K | Direct | Mar 15, 2024 (2d) |
| Jan 22, 2024 | RNA | ↓ Sell10b5-1 | 1,616 | $10.13 | $16K | Direct | Jan 23, 2024 (1d) |
| Aug 2, 2010 | BIIB | ↓ Sell | 9,542 | $56.85 | $542K | Direct | Aug 3, 2010 (1d) |
| Mar 19, 2010 | BIIB | ↓ Sell | 4,085 | $60.00 | $245K | Direct | Mar 23, 2010 (4d) |
| Jan 19, 2010 | BIIB | ↓ Sell | 1,389 | $55.00 | $76K | Direct | Jan 19, 2010 (0d) |
| Oct 6, 2008 | BIIB | ↓ Sell | 2,047 | $50.00 | $102K | Direct | Oct 6, 2008 (0d) |
| Jul 31, 2008 | BIIB | ↓ Sell | 1,875 | $72.77 | $136K | Direct | Aug 1, 2008 (1d) |
| Jul 22, 2008 | BIIB | ↓ Sell | 682 | $70.00 | $48K | Direct | Jul 24, 2008 (2d) |
| Apr 8, 2008 | BIIB | ↓ Sell | 2,214 | $64.37 | $143K | Direct | Apr 10, 2008 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RNA insiders
Open-market trades in the last 12 months
About Michael F MacLean's insider trades
Michael F MacLean is Chief Financial Officer at Avidity Biosciences (RNA). Since Apr 8, 2008, Michael has reported no open-market purchases and 19 sales worth $16.3M on SEC Form 4. In the last 12 months: 1 sale ($329K).
7 sales (12% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (26 filings), shares withheld for taxes (10 filings), option exercises (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.